Relapsing Remitting Multiple SclerosisPhase 4TOPAZNCT02255656
Phase IIIB-IV Long-Term Follow-up Study for Patients Who Participated in CAMMS03409
A Phase 4 study testing alemtuzumab GZ402673 in people with Relapsing Remitting Multiple Sclerosis, run by Genzyme, a Sanofi Company at 131 sites in 19 countries.
Trial summary
Primary Objective: To evaluate long-term safety of alemtuzumab. Secondary Objectives: To evaluate long term efficacy of alemtuzumab. To evaluate the safety profile of participants who received other Disease Modifying Treatment (DMT) following alemtuzumab treatment. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Relapsing Remitting Multiple Sclerosis
- What is being tested?
- alemtuzumab GZ402673
- Type of treatment
- Injection or infusion
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 1,062 participants
- Where
- 131 sitesin 19 countries
- Study dates
- 7 Jan 2015to 15 Jul 2020
- Phase
- Phase 4
- Are there results?
- Yes, posted in the registrySummary in the doctors' view
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Participant had completed at least 48 months of the Extension Study CAMMS03409. Signed written informed consent form.
Who cannot join
- Participant participating in another investigational interventional study.
- The above information was not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.
Trial locations and contacts
131 sites in 19 countries.
131 sites in 19 countries
United States52 sites
Investigational Site Number 1014
Albuquerque, New Mexico, 87131
Investigational Site Number 1097
Allentown, Pennsylvania, 18103
Investigational Site Number 1025
Ann Arbor, Michigan, 48105-2945
Investigational Site Number 1040
Berkeley, California, 94705
Investigational Site Number 1095
Chapel Hill, North Carolina, 27599
Investigational Site Number 1035
Cleveland, Ohio, 44195
Investigational Site Number 1163
Cordova, Tennessee, 38018
Investigational Site Number 1086
Cullman, Alabama, 00000
Investigational Site Number 1017
Des Moines, Iowa, 50314
Investigational Site Number 1020
Detroit, Michigan, 48201
Investigational Site Number 1027
Fort Collins, Colorado, 80528
Investigational Site Number 1001
Fort Wayne, Indiana, 46845
Investigational Site Number 1055
Franklin, Tennessee, 37064
Investigational Site Number 1152
Fullerton, California, 92835
Investigational Site Number 1018
Houston, Texas, 77030
Investigational Site Number 1024
Indianapolis, Indiana, 46202
Investigational Site Number 1078
Jacksonville, Florida, 32209
Investigational Site Number 1022
Kansas City, Kansas, 66160
Investigational Site Number 1084
Kansas City, Missouri, 64111
Investigational Site Number 1009
Knoxville, Tennessee, 37922
Investigational Site Number 1083
Lenexa, Kansas, 66214
Investigational Site Number 1039
Lexington, Kentucky, 40513
Investigational Site Number 1021
Louisville, Kentucky, 40202
Investigational Site Number 1059
Maitland, Florida, 32751
Investigational Site Number 1081
Mineola, New York, 11501
Investigational Site Number 1042
Nashville, Tennessee, 37215
Investigational Site Number 1026
New York, New York, 10029
Investigational Site Number 1008
Northbrook, Illinois, 60062
Investigational Site Number 1067
Oklahoma City, Oklahoma, 73104
Investigational Site Number 1093
Pasadena, California, 91105
Investigational Site Number 1160
Patchogue, New York, 11772
Investigational Site Number 1031
Phoenix, Arizona, 85013
Investigational Site Number 1171
Phoenix, Arizona, 85018
Investigational Site Number 1057
Providence, Rhode Island, 02905
Investigational Site Number 1015
Rochester, New York, 14642
Investigational Site Number 1002
Round Rock, Texas, 78681
Investigational Site Number 1046
San Antonio, Texas
Investigational Site Number 1173
Sarasota, Florida, 34239
Investigational Site Number 1068
Seattle, Washington, 98122
Investigational Site Number 1092
St Louis, Missouri, 63131
Investigational Site Number 1034
Sunrise, Florida, 33351
Investigational Site Number 1053
Syracuse, New York, 13202
Investigational Site Number 1005
Tampa, Florida, 33609
Investigational Site Number 1049
Tampa, Florida, 33612
Investigational Site Number 1073
Teaneck, New Jersey, 07666
Investigational Site Number 1054
Traverse City, Michigan, 49684
Investigational Site Number 1090
Tucson, Arizona, 85704
Investigational Site Number 1058
Uniontown, Ohio, 44685
Investigational Site Number 1037
Vienna, Virginia, 22182
Investigational Site Number 1061
Wellesley, Massachusetts, 02481
Investigational Site Number 1082
Winston-Salem, North Carolina, 27103
Investigational Site Number 1028
Worcester, Massachusetts, 01655
Russia11 sites
Investigational Site Number 6009
Kazan', 420097
Investigational Site Number 6001
Moscow, 1217015
Investigational Site Number 6005
Moscow, 1217015
Investigational Site Number 6003
Moscow
Investigational Site Number 6006
Nizhny Novgorod
Investigational Site Number 6010
Pyatigorsk
Investigational Site Number 6002
Saint Petersburg
Investigational Site Number 6004
Saint Petersburg
Investigational Site Number 6008
Saint Petersburg
Investigational Site Number 6013
Samara
Investigational Site Number 6016
Ufa
Australia9 sites
Investigational Site Number 2013
Auchenflower, 4066
Investigational Site Number 2001
Heidelberg, 3084
Investigational Site Number 2011
Hobart, 7000
Investigational Site Number 2012
Kogarah, 2217
Investigational Site Number 2003
Melbourne, 3065
Investigational Site Number 2002
Parkville, 3050
Investigational Site Number 2005
Southport, 4215
Investigational Site Number 2009
Sydney
Investigational Site Number 2006
Westmead, 2145
Germany9 sites
Investigational Site Number 4602
Berlin, 13347
Investigational Site Number 4607
Dresden, 01307
Investigational Site Number 4634
Frankfurt am Main, 60590
Investigational Site Number 4622
Hamburg, 22307
Investigational Site Number 4605
Hanover, 30625
Investigational Site Number 4609
Hennigsdorf, 16761
Investigational Site Number 4608
München, 81675
Investigational Site Number 4610
Rostock, 18147
Investigational Site Number 4613
Wermsdorf, 04779
Canada7 sites
Investigational Site Number 1102
Calgary, T2N 2T9
Investigational Site Number 1105
Gatineau, J8Y1W2
Investigational Site Number 1104
Greenfield Park, J4V2J2
Investigational Site Number 1109
Kingston, K7L2V7
Investigational Site Number 1110
London, N6A5A5
Investigational Site Number 1101
Ottawa, K1H8L6
Investigational Site Number 1106
Vancouver, V6T1Z3
United Kingdom6 sites
Investigational Site Number 4004
Bristol, BS105NB
Investigational Site Number 4001
Cambridge, CB50QQ
Investigational Site Number 4005
Cardiff, CF44XN
Investigational Site Number 4006
London, E12AT
Investigational Site Number 4008
Salford, M68HD
Investigational Site Number 4007
Sheffield, S102JF
Poland5 sites
Investigational Site Number 4902
Krakow, 31-505
Investigational Site Number 4901
Lodz, 90-324
Investigational Site Number 4903
Lublin, 20-090
Investigational Site Number 4904
Poznan, 60-355
Investigational Site Number 4905
Warsaw, 02-957
Brazil4 sites
Investigational Site Number 3006
Porto Alegre, 90110000
Investigational Site Number 3002
Recife, 52010-040
Investigational Site Number 3001
São Paulo, 01221-000
Investigational Site Number 3003
São Paulo, 05403-000
Czechia4 sites
Investigational Site Number 4803
Brno, 65691
Investigational Site Number 4804
Hradec Králové, 50005
Investigational Site Number 4801
Prague, 12808
Investigational Site Number 4802
Teplice, 41501
Italy4 sites
Investigational Site Number 4112
Cagliari, 09126
Investigational Site Number 4102
Gallarate (VA), 21013
Investigational Site Number 4106
Orbassano (TO), 10043
Investigational Site Number 4110
Roma, 00189
Spain4 sites
Investigational Site Number 4301
Barcelona, 08035
Investigational Site Number 4303
Madrid, 28040
Investigational Site Number 4305
Málaga, 29010
Investigational Site Number 4304
Seville, 41071
Belgium3 sites
Investigational Site Number 5005
Brussels, 1200
Investigational Site Number 5004
Esneux, 4130
Investigational Site Number 5001
Leuven, 3000
Ukraine3 sites
Investigational Site Number 6102
Kharkiv
Investigational Site Number 6104
Kiev
Investigational Site Number 6103
Lviv
Denmark2 sites
Investigational Site Number 5302
Aarhus N, 8200
Investigational Site Number 5301
København Ø, 2100
Israel2 sites
Investigational Site Number 5501
Ramat Gan, 52621
Investigational Site Number 5505
Tel Aviv
Mexico2 sites
Investigational Site Number 3105
Chihuahua City, 31203
Investigational Site Number 3102
México, 14260
Sweden2 sites
Investigational Site Number 4701
Gothenburg, 41345
Investigational Site Number 4702
Umeå, 90185
About this study
Official title: A Long-term Follow-up Study for Multiple Sclerosis Patients Who Have Completed the Alemtuzumab Extension Study (CAMMS03409)
Primary Objective:
To evaluate long-term safety of alemtuzumab.
Secondary Objectives:
- To evaluate long term efficacy of alemtuzumab.
- To evaluate the safety profile of participants who received other Disease Modifying Treatment (DMT) following alemtuzumab treatment.
- To evaluate participant-reported Quality of Life (QoL) outcomes and health resource utilization of participant who received alemtuzumab.
- To evaluate as needed re-treatment with alemtuzumab and other DMTs.
Read the detailed description
The total duration per participants was up to 5.6 years.
As per Study Investigator discretion, participants can be treated with additional courses of alemtuzumab or any commercialized DMTs.
All participants who completed CAMMS03409 were allowed into the study, which might include specific vulnerable populations. If the investigator decided to treat a participant with a course of alemtuzumab, appropriate cautionary measures were applied as indicated in the approved labelling, or, in ex-European Union countries where Lemtrada was not approved, according to the investigator's brochure.
- Conditions
- Relapsing Remitting Multiple Sclerosis
- Being tested
- alemtuzumab GZ402673
- Medical subject headings
- Multiple Sclerosis, Relapsing-Remitting
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
alemtuzumab GZ402673Drug
Pharmaceutical form:concentrate for solution for infusion Route of administration: intravenous
| Study group | Role | What they receive |
|---|---|---|
| Alemtuzumab | Experimental | All Participants who completed the study CAMMS03409 (extension study of CAMMS223 [NCT00050778], CAMMS323 [NCT00530348], or CAMMS324 [NCT00548405]) and received alemtuzumab within 48 months prior to enrollment were included in this LPS13649 study. Participants received alemtuzumab, intravenous infusion of 12 milligram per day (mg/day) for 3 consecutive days, at the study investigators' discretion; and at least 12 months after the prior treatment course in the current study (LPS13649). Receives: Drug: alemtuzumab GZ402673 |
What is being measured
The primary outcome is the main question the study is designed to answer.
Number of Participants With Treatment-Emergent Adverse Events (TEAEs), and Treatment-Emergent Serious Adverse Events (TESAEs)
An Adverse Event (AE) was any untoward medical occurrence in a participant administered a pharmaceutical product and which did not necessarily had to have causal relationship with treatment. TEAEs were defined as AEs that developed/worsened during the 'treatment period (time from Baseline until the end of the study LPS13649 [i.e. up to a maximum of 5.6 years]). Serious adverse events (SAEs) was any untoward medical occurrence that at any dose: resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, was a medically important event.
Measured: From Baseline until the end of the study (up to a maximum duration of 5.6 years)
Number of Participants With Infusion-Associated Reactions (IAR)
Infusion-associated reactions (IAR) was defined as any adverse event occurring during and within 24 hours of alemtuzumab infusion.
Measured: Within 24 hours of any alemtuzumab infusion
Number of Participants With Adverse Events of Special Interest (AESI)
Adverse events of special interest included the following: hypersensitivity or anaphylaxis; pregnancy of a woman entered in the study; symptomatic overdose (serious or non-serious) with investigational medicinal Product (IMP); increase in alanine transaminase (ALT); autoimmune mediated conditions; hemophagocytic lymphohistiocytosis; progressive multifocal leukoencephalopathy; temporally associated AEs; serious infections; malignancy; and pneumonitis.
Measured: From Baseline until the end of the study (up to a maximum duration of 5.6 years)
Number of Participants With Potentially Clinically Significant Laboratory Abnormalities
Criteria for potentially clinically significant laboratory abnormalities included:
- Hemoglobin (Hb): less than or equal to (<=)115 grams per liter (g/L)(Male [M]), <= 95 g/L (Female[ F]); greater than or equal to (>=)185 g/L (M), >= 165 g/L (F); Decrease From Baseline (DFB) >= 20 g/L.
- Hematocrit: <= 0.37 volume/volume (v/v) (M); <= 0.32 v/v (F); >= 0.55 v/v (M); >= 0.5 v/v (F).
- Red Blood Cells (RBCs): >=6 *10^12/L.
- Platelets: <100 *10^9/L; >=700 *10^9/L. As pre-specified, data collection and analysis for this outcome measure was done on the overall population along with 2 subgroups (DAT and IAT).
Measured: From Baseline until the end of the study (up to a maximum duration of 5.6 years)
Secondary outcomes (22)
Annualized Relapse Rate
Relapse was defined as new neurological symptoms or worsening of previous neurological symptoms with an objective change on neurological examination. Annualized relapse rate was obtained from the total number of confirmed relapses that occurred during the treatment follow up time of all participants divided by the total years of follow-up for all participants. The annualized relapse rate was estimated using a negative binomial model with robust variance estimation.
Measured: Up to a maximum duration of 5.6 years
Proportion of Participants Who Were Relapse Free
Relapse was defined as new neurological symptoms or worsening of previous neurological symptoms with an objective change on neurological examination. The proportion of participants who were relapse free (without event) were estimated using the Kaplan-Meier method.
Measured: Up to a maximum duration of 5.6 years
Change From Baseline in Expanded Disability Status Scale (EDSS) Score at Month 6, 12, 18, 24, 30, 36, 42, 48, 54 and 60
EDSS is an ordinal scale in half-point increments that qualifies disability in participants with multiple sclerosis (MS). It consists of 8 ordinal rating scales assessing seven functional systems (pyramidal, cerebellar, brainstem, sensory, bowel and bladder, visual, cerebral, and other). EDSS total score ranges from 0 (normal neurological examination) to 10 (death due to MS), where higher scores indicated worst outcomes.
Measured: Baseline (Month 0 of LPS13649), Month 6, 12, 18, 24, 30, 36, 42, 48, 54 and 60
Brain Magnetic Resonance Imaging (MRI) Assessment: Number of Gadolinium Enhancing (Gd-enhancing) Lesions Per MRI Scan
Number of Gd-enhancing lesions per scan was defined as the total number of Gd-enhancing lesions that occurred during the treatment period divided by the total number of scans performed during the treatment period. The adjusted cumulative count of lesions was estimated by a repeated negative binomial regression with generalized estimating equation (GEE) adjusted for analysis groups and geographic region as covariates.
Measured: Up to a maximum duration of 5.6 years
Brain Magnetic Resonance Imaging (MRI) Assessment: Number of New or Enlarged T2 Lesions Per MRI Scan
Number of new or enlarged T2 lesions per scan was defined as the total number of new or enlarged T2 lesion that occurred during treatment period divided by the total number of scans performed during treatment period. The adjusted cumulative count of lesions was estimated by a repeated negative binomial regression with GEE adjusted for analysis groups and geographic region as covariates.
Measured: Up to a maximum duration of 5.6 years
Brain Magnetic Resonance Imaging (MRI) Assessment: Number of New T1 (and New Hypointense T1) Lesions Per MRI Scan
Number of new T1 lesions per scan was defined as the total number of new T1 lesion (and New Hypointense T1) that occurred during treatment period divided by the total number of scans performed during treatment period.The adjusted cumulative count of lesions was estimated by a repeated negative binomial regression with GEE adjusted for analysis groups and geographic region as covariates.
Measured: Up to a maximum duration of 5.6 years
Brain Magnetic Resonance Imaging (MRI) Assessment: Percent Change From Baseline in Volume of T1 Lesions at Months 12, 24, 36, 48, and 60
The total lesion volume (T1 lesions) was measured by MRI scan.
Measured: Baseline (Month 0 of LPS13649), Month 12, Month 24, Month 36, Month 48 and Month 60
Brain Magnetic Resonance Imaging (MRI) Assessment: Percent Change From Baseline in Volume of T2 Lesions at Months 12, 24, 36, 48, and 60
The total lesion volume (T2 lesions) was measured by MRI scan.
Measured: Baseline (Month 0 of LPS13649), Month 12, Month 24, Month 36, Month 48 and Month 60
Brain Magnetic Resonance Imaging (MRI) Assessment: Percent Change From Baseline in Brain Parenchymal Fraction (BPF) at Month 12, 24, 36, 48, and 60
The brain parenchymal fraction was measured by MRI scan.
Measured: Baseline (Month 0 of LPS13649), Month 12, Month 24, Month 36, Month 48 and Month 60
Change From Baseline in Self-reported Quality of Life (QoL) as Assessed by the Medical Outcome Study (MOS) 36-Item Short-Form Health Survey (SF-36): Physical Component Summary (PCS) and Mental Component Summary (MCS) Scores at Month 12, 24, 36, 48, and 60
The MOS SF-36 is an extensively validated and widely used measure of QoL that assesses participants' perceptions of health status and its impact on their lives. It consisted of 36 items organized into 8 scales (physical functioning, role physical, bodily pain, general health, vitality, social functioning, role emotional and mental health). Two summary measures of physical and mental health, the PCS and MCS, respectively, were derived from scale aggregates, and were reported in this outcome measure. The score range for each of these 2 summary scores was from 0 (worst) to 100 (best), higher scores indicated better QoL.
Measured: Baseline (Month 0 of LPS13649), Month 12, Month 24, Month 36, Month 48 and Month 60
Change From Baseline in Functional Assessment of Multiple Sclerosis (FAMS) Score at Month 12, 24, 36, 48, and 60
The FAMS is a self-reported multidimensional index comprising a total of 58 items on 7 subscales: mobility (7 items); symptoms (7 items); emotional well-being (7 items); general contentment (7 items); thinking and fatigue (9 items); family/social well-being (7 items); and additional concerns (14 items, these are not scored). Each item (except those for "additional concerns") was rated on a 5-point scale of 0 (lower quality of life) to 4 (higher quality of life). Total FAMS score was the sum of 44 scored items, which ranged from 0 (poor) to 176 (best), with higher numbers reflecting a higher quality of life.
Measured: Baseline (Month 0 of LPS13649), Month 12, Month 24, Month 36, Month 48 and Month 60
Change From Baseline in European Quality of Life -5 Dimension (EQ-5D) Score: Utility Scores at Month 12, 24, 36, 48, and 60
The EQ-5D is a generic, standardized instrument that provides a simple, descriptive profile and a single index value for health status used in the clinical and economic evaluation of health care as well as in population health surveys. The EQ-5D comprises 5 dimensions of health: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension measured on 3 levels: some, moderate, and extreme problems. The 5 dimensional 3-level systems was converted into single index utility score ranges from 0 to 100, where 100=best health state; and 0=worst health state; higher scores indicated better outcome.
Measured: Baseline (Month 0 of LPS13649), Month 12, Month 24, Month 36, Month 48 and Month 60
Change From Baseline in EQ-5D Visual Analogue Scale (VAS) Scores at Month 12, 24, 36, 48, and 60
EQ-5D VAS was used to record a participant's rating for his/her current health-related quality of life state and captured on a vertical VAS (0 to 100), where 0=worst imaginable health state to 100=best imaginable health state, and higher score indicated better outcome.
Measured: Baseline (Month 0 of LPS13649), Month 12, Month 24, Month 36, Month 48 and Month 60
Modified Healthcare Resource Utilization Questionnaire (HRUQ): Number of Participants Who Reported Change in Employment Situation, Availing of Sick Leaves, Admissions and Stays in Hospital, Rehabilitation Centers or Nursing Homes Due to Multiple Sclerosis
Participants use of healthcare resources, non-medical resources, and informal care as well as their work capacity was assessed at scheduled study visits using a modified questionnaire (HRUQ) designed to evaluate the economic impact of MS. Questionnaire addresses the following content areas: employment situation and changes in employment situation due to MS;sick leaves,admissions and stays in hospital, rehabilitation centers, or nursing homes; typical MS-related investments (eg, stair and bed lift, ramps,rails) and devices (eg,walking aids,wheelchairs); assistance by community or social services (e.g. home nurse, transportation), or help from family or friends. Each question requires a binary answer (yes/no). Number of participants who reported "Yes" as an answer to "employment situation change; had sick leaves; had hospital admission; had spent time in rehabilitation center and had spent time in a nursing home or a similar institution" questions were reported in this outcome measure.
Measured: Baseline (Month 0 of LPS13649), Month 12, Month 24, Month 36, Month 48 and Month 60
Modified HRUQ: Number of Participants Who Reported Other Changes/Changes in Lifestyle Due to Multiple Sclerosis
Participants use of healthcare resources, non-medical resources, and informal care as well as their work capacity was assessed at scheduled study visits using a modified questionnaire (HRUQ) designed to evaluate the economic impact of MS.Questionnaire addresses following content areas: employment situation and changes in employment situation due to MS; admissions and stays in hospital, rehabilitation centers, or nursing homes; typical MS-related investments(e.g.stair and bed lift,ramps,rails) and devices(e.g.walking aids,wheelchairs);assistance by community or social services(e.g.home nurse, transportation), or help from family or friends. Each question requires a binary answer (yes/no). Number of participants who reported other changes/changes in lifestyle due to MS, i.e."Yes" as an answer to "had made changes to your house, apartment, car or did you require any special equipment or aids; assistance required; other assistance required" questions were reported in this outcome measure.
Measured: Baseline (Month 0 of LPS13649), Month 12, Month 24, Month 36, Month 48 and Month 60
Health Related Productivity Questionnaire (HRPQ): Number of Participants Reporting Current Employment Status (Part Time/Full Time/Not Employed) Due to Multiple Sclerosis
Participants use of healthcare resources, non-medical resources, and informal care as well as their work capacity was assessed at scheduled study visits using a modified questionnaire (HRPQ) designed to evaluate the economic impact of MS. The questionnaire addresses the following content area: participant reported data regarding employment status, work productivity, impact on household chores due to MS. Current employment status of participants (i.e. Part Time/Full Time/Not Employed) was reported in this outcome measure.
Measured: Baseline (Month 0 of LPS13649), Month 12, Month 24, Month 36, Month 48 and Month 60
HRPQ: Total Scheduled Working Hours and Number of Hours Missed From Work Due to Multiple Sclerosis
Participants use of healthcare resources, non-medical resources, and informal care as well as their work capacity was assessed at scheduled study visits using a modified questionnaire (HRPQ) designed to evaluate the economic impact of MS. The questionnaire addresses the following content area: participant reported data regarding employment status, work productivity, impact on household chores due to MS. Data for "total scheduled working hours of participants; number of hours missed from work by participants due to MS" were reported in this outcome measure.
Measured: Baseline (Month 0 of LPS13649), Month 12, Month 24, Month 36, Month 48 and Month 60
HRPQ: Percentage Impact on Work Output Due to Multiple Sclerosis
Participants use of healthcare resources, non-medical resources, and informal care as well as their work capacity was assessed at scheduled study visits using a modified questionnaire (HRPQ) designed to evaluate the economic impact of MS. The questionnaire addresses the following content area: participant reported data regarding employment status, work productivity, impact on household chores due to MS. Percentage impact on work output due to MS were reported in this outcome measure.
Measured: Baseline (Month 0 of LPS13649), Month 12, Month 24, Month 36, Month 48 and Month 60
HRPQ: Total Scheduled Household Chores Hours; Number of Hours Missed From Household Chores Due to Multiple Sclerosis
Participants use of healthcare resources, non-medical resources, and informal care as well as their work capacity was assessed at scheduled study visits using a modified questionnaire (HRPQ) designed to evaluate the economic impact of MS. The questionnaire addresses the following content area: participant reported data regarding employment status, work productivity, impact on household chores due to MS. Data for "total scheduled household chores hours; number of hours missed from planned household chores by participants due to MS" were reported in this outcome measure.
Measured: Baseline (Month 0 of LPS13649), Month 12, Month 24, Month 36, Month 48 and Month 60
HRPQ: Percentage Impact on Work Output for Household Chores Due to Multiple Sclerosis
Participants use of healthcare resources, non-medical resources, and informal care as well as their work capacity was assessed at scheduled study visits using a modified questionnaire (HRPQ) designed to evaluate the economic impact of MS. The questionnaire addresses the following content area: participant reported data regarding employment status, work productivity, impact on household chores due to MS. Percentage impact on work output for household chores due to MS were reported in this outcome measure.
Measured: Baseline (Month 0 of LPS13649), Month 12, Month 24, Month 36, Month 48 and Month 60
HRPQ: Duration of Disease (in Months) Since Development of Multiple Sclerosis
Participants use of healthcare resources, non-medical resources, and informal care as well as their work capacity was assessed at scheduled study visits using a modified questionnaire (HRPQ) designed to evaluate the economic impact of MS. The questionnaire addresses the following content area: participant reported data regarding employment status, work productivity, impact on household chores due to MS. Mean and standard deviation data for duration of MS disease (in months) since the start of MS development in participants was reported in this outcome measure.
Measured: Baseline up to end of the study (up to a maximum duration of 5.6 years)
HRPQ: Number of Participants Who Reported Impact on Work Due to Multiple Sclerosis
Participants use of healthcare resources, non-medical resources, and informal care as well as their work capacity was assessed at scheduled study visits using a modified questionnaire (HRPQ) designed to evaluate the economic impact of MS. The questionnaire addresses the following content area: participant reported data regarding employment status, work productivity, impact on household chores due to MS. Number of participants who reported "Yes" as an answer to questions related to impact on work: "forced me to work part-time when I wanted to work full-time; kept me from having a job when I wanted to work full-time; kept me from having a job when I wanted to work part-time; none of the above" questions were reported in this outcome measure.
Measured: Baseline up to end of the study (up to a maximum duration of 5.6 years)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted2 Oct 2014 (estimated)
- Study start7 Jan 2015
- Primary completion15 Jul 2020
- Study completion15 Jul 2020
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Publications (9)Papers the sponsor has linked to this study.
- Other trials for Relapsing Remitting Multiple SclerosisStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 4
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 1,062 participants (actual)
Sponsor and investigators
- Lead sponsor
- Genzyme, a Sanofi Company
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Clinical Sciences & Operations, Study director, Sanofi
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02255656
- Sponsor's protocol ID
- LPS13649
- Other IDs
- 2013-003884-71, U1111-1148-2987
- Acronym
- TOPAZ
- Status last verified
- Mar 2022
- First submitted
- 30 Sep 2014
- Last updated
- 28 Mar 2022
- Results posted
- Yes, on ClinicalTrials.gov
- Data monitoring committee
- No
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
- Individual data sharing
- Yes: Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org
Publications
Ziemssen T, Bass AD, Van Wijmeersch B, Eichau S, Richter S, Hoffmann F, Armstrong NM, Chirieac M, Cunha-Santos J, Singer BA. Long-term efficacy and safety of alemtuzumab in participants with highly active MS: TOPAZ clinical trial and interim analysis of TREAT-MS real-world study. Ther Adv Neurol Disord. 2025 Feb 10;18:17562864241306575. doi: 10.1177/17562864241306575. eCollection 2025.
PubMed 39935588Coles AJ, Achiron A, Traboulsee A, Singer BA, Pozzilli C, Oreja-Guevara C, Giovannoni G, Comi G, Freedman MS, Ziemssen T, Shiota D, Rawlings AM, Wong AT, Chirieac M, Montalban X. Safety and efficacy with alemtuzumab over 13 years in relapsing-remitting multiple sclerosis: final results from the open-label TOPAZ study. Ther Adv Neurol Disord. 2023 Sep 21;16:17562864231194823. doi: 10.1177/17562864231194823. eCollection 2023.
PubMed 37745914Coles AJ, Jones JL, Vermersch P, Traboulsee A, Bass AD, Boster A, Chan A, Comi G, Fernandez O, Giovannoni G, Kubala Havrdova E, LaGanke C, Montalban X, Oreja-Guevara C, Piehl F, Wiendl H, Ziemssen T. Autoimmunity and long-term safety and efficacy of alemtuzumab for multiple sclerosis: Benefit/risk following review of trial and post-marketing data. Mult Scler. 2022 Apr;28(5):842-846. doi: 10.1177/13524585211061335. Epub 2021 Dec 9.
PubMed 34882037Kuhle J, Daizadeh N, Benkert P, Maceski A, Barro C, Michalak Z, Sormani MP, Godin J, Shankara S, Samad TA, Jacobs A, Chung L, Rӧsch N, Kaiser C, Mitchell CP, Leppert D, Havari E, Kappos L. Sustained reduction of serum neurofilament light chain over 7 years by alemtuzumab in early relapsing-remitting MS. Mult Scler. 2022 Apr;28(4):573-582. doi: 10.1177/13524585211032348. Epub 2021 Aug 11.
PubMed 34378446Bass AD, Arroyo R, Boster AL, Boyko AN, Eichau S, Ionete C, Limmroth V, Navas C, Pelletier D, Pozzilli C, Ravenscroft J, Sousa L, Tintore M, Uitdehaag BMJ, Baker DP, Daizadeh N, Choudhry Z, Rog D; CARE-MS I, CARE-MS II, CAMMS03409, and TOPAZ investigators. Alemtuzumab outcomes by age: Post hoc analysis from the randomized CARE-MS studies over 8 years. Mult Scler Relat Disord. 2021 Apr;49:102717. doi: 10.1016/j.msard.2020.102717. Epub 2020 Dec 24.
PubMed 33476880Ziemssen T, Bass AD, Berkovich R, Comi G, Eichau S, Hobart J, Hunter SF, LaGanke C, Limmroth V, Pelletier D, Pozzilli C, Schippling S, Sousa L, Traboulsee A, Uitdehaag BMJ, Van Wijmeersch B, Choudhry Z, Daizadeh N, Singer BA; CARE-MS I, CARE-MS II, CAMMS03409, and TOPAZ investigators. Efficacy and Safety of Alemtuzumab Through 9 Years of Follow-up in Patients with Highly Active Disease: Post Hoc Analysis of CARE-MS I and II Patients in the TOPAZ Extension Study. CNS Drugs. 2020 Sep;34(9):973-988. doi: 10.1007/s40263-020-00749-x.
PubMed 32710396Steingo B, Al Malik Y, Bass AD, Berkovich R, Carraro M, Fernandez O, Ionete C, Massacesi L, Meuth SG, Mitsikostas DD, Pardo G, Simm RF, Traboulsee A, Choudhry Z, Daizadeh N, Compston DAS; CAMMS223, CAMMS03409, and TOPAZ Investigators. Long-term efficacy and safety of alemtuzumab in patients with RRMS: 12-year follow-up of CAMMS223. J Neurol. 2020 Nov;267(11):3343-3353. doi: 10.1007/s00415-020-09983-1. Epub 2020 Jun 24.
PubMed 32583052Comi G, Alroughani R, Boster AL, Bass AD, Berkovich R, Fernandez O, Kim HJ, Limmroth V, Lycke J, Macdonell RA, Sharrack B, Singer BA, Vermersch P, Wiendl H, Ziemssen T, Jacobs A, Daizadeh N, Rodriguez CE, Traboulsee A; CARE-MS I, CARE-MS II, CAMMS03409, and TOPAZ Investigators. Efficacy of alemtuzumab in relapsing-remitting MS patients who received additional courses after the initial two courses: Pooled analysis of the CARE-MS, extension, and TOPAZ studies. Mult Scler. 2020 Dec;26(14):1866-1876. doi: 10.1177/1352458519888610. Epub 2019 Nov 25.
PubMed 31762387Okai AF, Amezcua L, Berkovich RR, Chinea AR, Edwards KR, Steingo B, Walker A, Jacobs AK, Daizadeh N, Williams MJ; CARE-MS I, CARE-MS II, CAMMS03409, and TOPAZ Investigators. Efficacy and Safety of Alemtuzumab in Patients of African Descent with Relapsing-Remitting Multiple Sclerosis: 8-Year Follow-up of CARE-MS I and II (TOPAZ Study). Neurol Ther. 2019 Dec;8(2):367-381. doi: 10.1007/s40120-019-00159-2. Epub 2019 Oct 25.
PubMed 31654272
Study at a glance
From the registry record, last updated by the sponsor on 28 Mar 2022. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Long-term Follow-up Study for Multiple Sclerosis Patients Who Have Completed the Alemtuzumab Extension Study (CAMMS03409)
- ClinicalTrials.gov ID
- NCT02255656
- Acronym / sponsor ID
- TOPAZ / LPS13649
- Conditions
- Relapsing Remitting Multiple Sclerosis
- Phase
- Phase 4
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 1,062 participants (actual)
- Lead sponsor
- Genzyme, a Sanofi CompanyIndustry (pharma, biotech, devices)
- Study start
- 7 Jan 2015 (actual)
- Primary completion
- 15 Jul 2020 (actual)
- Study completion
- 15 Jul 2020 (actual)
- First posted
- 2 Oct 2014 (estimated)
- Results
- Posted 23 Jul 2021
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Primary Objective:
To evaluate long-term safety of alemtuzumab.
Secondary Objectives:
- To evaluate long term efficacy of alemtuzumab.
- To evaluate the safety profile of participants who received other Disease Modifying Treatment (DMT) following alemtuzumab treatment.
- To evaluate participant-reported Quality of Life (QoL) outcomes and health resource utilization of participant who received alemtuzumab.
- To evaluate as needed re-treatment with alemtuzumab and other DMTs.
Detailed description
The total duration per participants was up to 5.6 years.
As per Study Investigator discretion, participants can be treated with additional courses of alemtuzumab or any commercialized DMTs.
All participants who completed CAMMS03409 were allowed into the study, which might include specific vulnerable populations. If the investigator decided to treat a participant with a course of alemtuzumab, appropriate cautionary measures were applied as indicated in the approved labelling, or, in ex-European Union countries where Lemtrada was not approved, according to the investigator's brochure.
Study design
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Alemtuzumab | Experimental | Drug: alemtuzumab GZ402673All Participants who completed the study CAMMS03409 (extension study of CAMMS223 [NCT00050778], CAMMS323 [NCT00530348], or CAMMS324 [NCT00548405]) and received alemtuzumab within 48 months prior to enrollment were included in this LPS13649 study. Participants received alemtuzumab, intravenous infusion of 12 milligram per day (mg/day) for 3 consecutive days, at the study investigators' discretion; and at least 12 months after the prior treatment course in the current study (LPS13649). |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (1 listed)
- Participant had completed at least 48 months of the Extension Study CAMMS03409. Signed written informed consent form.
Key exclusion criteria (2 listed)
- Participant participating in another investigational interventional study.
- The above information was not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| alemtuzumab GZ402673Pharmaceutical form:concentrate for solution for infusion Route of administration: intravenous | Drug | Alemtuzumab |
Primary outcome
Number of Participants With Treatment-Emergent Adverse Events (TEAEs), and Treatment-Emergent Serious Adverse Events (TESAEs)
Time frame: From Baseline until the end of the study (up to a maximum duration of 5.6 years)
An Adverse Event (AE) was any untoward medical occurrence in a participant administered a pharmaceutical product and which did not necessarily had to have causal relationship with treatment. TEAEs were defined as AEs that developed/worsened during the 'treatment period (time from Baseline until the end of the study LPS13649 [i.e. up to a maximum of 5.6 years]). Serious adverse events (SAEs) was any untoward medical occurrence that at any dose: resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, was a medically important event.
Number of Participants With Infusion-Associated Reactions (IAR)
Time frame: Within 24 hours of any alemtuzumab infusion
Infusion-associated reactions (IAR) was defined as any adverse event occurring during and within 24 hours of alemtuzumab infusion.
Number of Participants With Adverse Events of Special Interest (AESI)
Time frame: From Baseline until the end of the study (up to a maximum duration of 5.6 years)
Adverse events of special interest included the following: hypersensitivity or anaphylaxis; pregnancy of a woman entered in the study; symptomatic overdose (serious or non-serious) with investigational medicinal Product (IMP); increase in alanine transaminase (ALT); autoimmune mediated conditions; hemophagocytic lymphohistiocytosis; progressive multifocal leukoencephalopathy; temporally associated AEs; serious infections; malignancy; and pneumonitis.
Number of Participants With Potentially Clinically Significant Laboratory Abnormalities
Time frame: From Baseline until the end of the study (up to a maximum duration of 5.6 years)
Criteria for potentially clinically significant laboratory abnormalities included: * Hemoglobin (Hb): less than or equal to (<=)115 grams per liter (g/L)(Male [M]), <= 95 g/L (Female[ F]); greater than or equal to (>=)185 g/L (M), >= 165 g/L (F); Decrease From Baseline (DFB) >= 20 g/L. * Hematocrit: <= 0.37 volume/volume (v/v) (M); <= 0.32 v/v (F); >= 0.55 v/v (M); >= 0.5 v/v (F). * Red Blood Cells (RBCs): >=6 *10^12/L. * Platelets: <100 *10^9/L; >=700 *10^9/L. As pre-specified, data collection and analysis for this outcome measure was done on the overall population along with 2 subgroups (DAT and IAT).
22 secondary outcomes
Annualized Relapse Rate
Time frame: Up to a maximum duration of 5.6 years
Proportion of Participants Who Were Relapse Free
Time frame: Up to a maximum duration of 5.6 years
Change From Baseline in Expanded Disability Status Scale (EDSS) Score at Month 6, 12, 18, 24, 30, 36, 42, 48, 54 and 60
Time frame: Baseline (Month 0 of LPS13649), Month 6, 12, 18, 24, 30, 36, 42, 48, 54 and 60
Brain Magnetic Resonance Imaging (MRI) Assessment: Number of Gadolinium Enhancing (Gd-enhancing) Lesions Per MRI Scan
Time frame: Up to a maximum duration of 5.6 years
Brain Magnetic Resonance Imaging (MRI) Assessment: Number of New or Enlarged T2 Lesions Per MRI Scan
Time frame: Up to a maximum duration of 5.6 years
Brain Magnetic Resonance Imaging (MRI) Assessment: Number of New T1 (and New Hypointense T1) Lesions Per MRI Scan
Time frame: Up to a maximum duration of 5.6 years
Brain Magnetic Resonance Imaging (MRI) Assessment: Percent Change From Baseline in Volume of T1 Lesions at Months 12, 24, 36, 48, and 60
Time frame: Baseline (Month 0 of LPS13649), Month 12, Month 24, Month 36, Month 48 and Month 60
Brain Magnetic Resonance Imaging (MRI) Assessment: Percent Change From Baseline in Volume of T2 Lesions at Months 12, 24, 36, 48, and 60
Time frame: Baseline (Month 0 of LPS13649), Month 12, Month 24, Month 36, Month 48 and Month 60
Brain Magnetic Resonance Imaging (MRI) Assessment: Percent Change From Baseline in Brain Parenchymal Fraction (BPF) at Month 12, 24, 36, 48, and 60
Time frame: Baseline (Month 0 of LPS13649), Month 12, Month 24, Month 36, Month 48 and Month 60
Change From Baseline in Self-reported Quality of Life (QoL) as Assessed by the Medical Outcome Study (MOS) 36-Item Short-Form Health Survey (SF-36): Physical Component Summary (PCS) and Mental Component Summary (MCS) Scores at Month 12, 24, 36, 48, and 60
Time frame: Baseline (Month 0 of LPS13649), Month 12, Month 24, Month 36, Month 48 and Month 60
Change From Baseline in Functional Assessment of Multiple Sclerosis (FAMS) Score at Month 12, 24, 36, 48, and 60
Time frame: Baseline (Month 0 of LPS13649), Month 12, Month 24, Month 36, Month 48 and Month 60
Change From Baseline in European Quality of Life -5 Dimension (EQ-5D) Score: Utility Scores at Month 12, 24, 36, 48, and 60
Time frame: Baseline (Month 0 of LPS13649), Month 12, Month 24, Month 36, Month 48 and Month 60
Change From Baseline in EQ-5D Visual Analogue Scale (VAS) Scores at Month 12, 24, 36, 48, and 60
Time frame: Baseline (Month 0 of LPS13649), Month 12, Month 24, Month 36, Month 48 and Month 60
Modified Healthcare Resource Utilization Questionnaire (HRUQ): Number of Participants Who Reported Change in Employment Situation, Availing of Sick Leaves, Admissions and Stays in Hospital, Rehabilitation Centers or Nursing Homes Due to Multiple Sclerosis
Time frame: Baseline (Month 0 of LPS13649), Month 12, Month 24, Month 36, Month 48 and Month 60
Modified HRUQ: Number of Participants Who Reported Other Changes/Changes in Lifestyle Due to Multiple Sclerosis
Time frame: Baseline (Month 0 of LPS13649), Month 12, Month 24, Month 36, Month 48 and Month 60
Health Related Productivity Questionnaire (HRPQ): Number of Participants Reporting Current Employment Status (Part Time/Full Time/Not Employed) Due to Multiple Sclerosis
Time frame: Baseline (Month 0 of LPS13649), Month 12, Month 24, Month 36, Month 48 and Month 60
HRPQ: Total Scheduled Working Hours and Number of Hours Missed From Work Due to Multiple Sclerosis
Time frame: Baseline (Month 0 of LPS13649), Month 12, Month 24, Month 36, Month 48 and Month 60
HRPQ: Percentage Impact on Work Output Due to Multiple Sclerosis
Time frame: Baseline (Month 0 of LPS13649), Month 12, Month 24, Month 36, Month 48 and Month 60
HRPQ: Total Scheduled Household Chores Hours; Number of Hours Missed From Household Chores Due to Multiple Sclerosis
Time frame: Baseline (Month 0 of LPS13649), Month 12, Month 24, Month 36, Month 48 and Month 60
HRPQ: Percentage Impact on Work Output for Household Chores Due to Multiple Sclerosis
Time frame: Baseline (Month 0 of LPS13649), Month 12, Month 24, Month 36, Month 48 and Month 60
HRPQ: Duration of Disease (in Months) Since Development of Multiple Sclerosis
Time frame: Baseline up to end of the study (up to a maximum duration of 5.6 years)
HRPQ: Number of Participants Who Reported Impact on Work Due to Multiple Sclerosis
Time frame: Baseline up to end of the study (up to a maximum duration of 5.6 years)
Results and safety
Loading the posted results from ClinicalTrials.gov…
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 28 Mar 2022.
- Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
- Derived from this study: PubMed 39935588Ziemssen T, Bass AD, Van Wijmeersch B, Eichau S, Richter S, Hoffmann F, Armstrong NM, Chirieac M, Cunha-Santos J, Singer BA. Long-term efficacy and safety of alemtuzumab in participants with highly active MS: TOPAZ clinical trial and interim analysis of TREAT-MS real-world study. Ther Adv Neurol Disord. 2025 Feb 10;18:17562864241306575. doi: 10.1177/17562864241306575. eCollection 2025.
- Derived from this study: PubMed 37745914Coles AJ, Achiron A, Traboulsee A, Singer BA, Pozzilli C, Oreja-Guevara C, Giovannoni G, Comi G, Freedman MS, Ziemssen T, Shiota D, Rawlings AM, Wong AT, Chirieac M, Montalban X. Safety and efficacy with alemtuzumab over 13 years in relapsing-remitting multiple sclerosis: final results from the open-label TOPAZ study. Ther Adv Neurol Disord. 2023 Sep 21;16:17562864231194823. doi: 10.1177/17562864231194823. eCollection 2023.
- Derived from this study: PubMed 34882037Coles AJ, Jones JL, Vermersch P, Traboulsee A, Bass AD, Boster A, Chan A, Comi G, Fernandez O, Giovannoni G, Kubala Havrdova E, LaGanke C, Montalban X, Oreja-Guevara C, Piehl F, Wiendl H, Ziemssen T. Autoimmunity and long-term safety and efficacy of alemtuzumab for multiple sclerosis: Benefit/risk following review of trial and post-marketing data. Mult Scler. 2022 Apr;28(5):842-846. doi: 10.1177/13524585211061335. Epub 2021 Dec 9.
- Derived from this study: PubMed 34378446Kuhle J, Daizadeh N, Benkert P, Maceski A, Barro C, Michalak Z, Sormani MP, Godin J, Shankara S, Samad TA, Jacobs A, Chung L, Rӧsch N, Kaiser C, Mitchell CP, Leppert D, Havari E, Kappos L. Sustained reduction of serum neurofilament light chain over 7 years by alemtuzumab in early relapsing-remitting MS. Mult Scler. 2022 Apr;28(4):573-582. doi: 10.1177/13524585211032348. Epub 2021 Aug 11.
- Derived from this study: PubMed 33476880Bass AD, Arroyo R, Boster AL, Boyko AN, Eichau S, Ionete C, Limmroth V, Navas C, Pelletier D, Pozzilli C, Ravenscroft J, Sousa L, Tintore M, Uitdehaag BMJ, Baker DP, Daizadeh N, Choudhry Z, Rog D; CARE-MS I, CARE-MS II, CAMMS03409, and TOPAZ investigators. Alemtuzumab outcomes by age: Post hoc analysis from the randomized CARE-MS studies over 8 years. Mult Scler Relat Disord. 2021 Apr;49:102717. doi: 10.1016/j.msard.2020.102717. Epub 2020 Dec 24.
- Derived from this study: PubMed 32710396Ziemssen T, Bass AD, Berkovich R, Comi G, Eichau S, Hobart J, Hunter SF, LaGanke C, Limmroth V, Pelletier D, Pozzilli C, Schippling S, Sousa L, Traboulsee A, Uitdehaag BMJ, Van Wijmeersch B, Choudhry Z, Daizadeh N, Singer BA; CARE-MS I, CARE-MS II, CAMMS03409, and TOPAZ investigators. Efficacy and Safety of Alemtuzumab Through 9 Years of Follow-up in Patients with Highly Active Disease: Post Hoc Analysis of CARE-MS I and II Patients in the TOPAZ Extension Study. CNS Drugs. 2020 Sep;34(9):973-988. doi: 10.1007/s40263-020-00749-x.
- Derived from this study: PubMed 32583052Steingo B, Al Malik Y, Bass AD, Berkovich R, Carraro M, Fernandez O, Ionete C, Massacesi L, Meuth SG, Mitsikostas DD, Pardo G, Simm RF, Traboulsee A, Choudhry Z, Daizadeh N, Compston DAS; CAMMS223, CAMMS03409, and TOPAZ Investigators. Long-term efficacy and safety of alemtuzumab in patients with RRMS: 12-year follow-up of CAMMS223. J Neurol. 2020 Nov;267(11):3343-3353. doi: 10.1007/s00415-020-09983-1. Epub 2020 Jun 24.
- Derived from this study: PubMed 31762387Comi G, Alroughani R, Boster AL, Bass AD, Berkovich R, Fernandez O, Kim HJ, Limmroth V, Lycke J, Macdonell RA, Sharrack B, Singer BA, Vermersch P, Wiendl H, Ziemssen T, Jacobs A, Daizadeh N, Rodriguez CE, Traboulsee A; CARE-MS I, CARE-MS II, CAMMS03409, and TOPAZ Investigators. Efficacy of alemtuzumab in relapsing-remitting MS patients who received additional courses after the initial two courses: Pooled analysis of the CARE-MS, extension, and TOPAZ studies. Mult Scler. 2020 Dec;26(14):1866-1876. doi: 10.1177/1352458519888610. Epub 2019 Nov 25.
- Derived from this study: PubMed 31654272Okai AF, Amezcua L, Berkovich RR, Chinea AR, Edwards KR, Steingo B, Walker A, Jacobs AK, Daizadeh N, Williams MJ; CARE-MS I, CARE-MS II, CAMMS03409, and TOPAZ Investigators. Efficacy and Safety of Alemtuzumab in Patients of African Descent with Relapsing-Remitting Multiple Sclerosis: 8-Year Follow-up of CARE-MS I and II (TOPAZ Study). Neurol Ther. 2019 Dec;8(2):367-381. doi: 10.1007/s40120-019-00159-2. Epub 2019 Oct 25.
- Individual participant dataSharing planned: Yes. Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org
Related trials for Relapsing Remitting Multiple Sclerosis
Active, not recruiting
Tai Chi Training for Persons With Multiple Sclerosis.
Multiple Sclerosis (MS) - Relapsing-remitting
RecruitingPhase 2
The HIt HArd and hiT Early in Multiple Sclerosis Trial
Relapsing-remitting Multiple Sclerosis
RecruitingPhase 3
Best Available Therapy Versus Autologous Hematopoietic Stem Cell Transplant for Multiple Sclerosis (BEAT-MS)
Relapsing Multiple Sclerosis, Relapsing Remitting Multiple Sclerosis
RecruitingObservational study
Early Versus Delayed Start of Ocrevus Zunovo for Relapsing Multiple Sclerosis
Relapse Remitting Multiple Sclerosis
Not yet recruitingPhase 2
A Study to Evaluate Pharmacokinetics, Safety, Tolerability, Immunogenicity and Pharmacodynamic Effects of Subcutaneous Ocrelizumab Administration in Children and Adolescents With Relapsing-remitting Multiple Sclerosis (RRMS)
Relapsing-remitting Multiple Sclerosis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Clinical Sciences & Operations study director
Sanofi
131 sites in 19 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 4 study testing alemtuzumab GZ402673 in people with Relapsing Remitting Multiple Sclerosis, run by Genzyme, a Sanofi Company at 131 sites in 19 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 28 Mar 2022. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 131 sites in United States, Russia, Australia, Germany, Canada and 14 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 4 studies take place after a treatment is approved, to learn more about its long-term benefits and risks in everyday use.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
Yes. Results are posted in the registry (first posted 23 Jul 2021). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Number of Participants With Treatment-Emergent Adverse Events (TEAEs), and Treatment-Emergent Serious Adverse Events (TESAEs) (time frame: From Baseline until the end of the study (up to a maximum duration of 5.6 years)). The study lists 4 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT02255656, which also lists 9 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 28 Mar 2022.